BR112021024491A8 - Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição - Google Patents

Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição

Info

Publication number
BR112021024491A8
BR112021024491A8 BR112021024491A BR112021024491A BR112021024491A8 BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8 BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8
Authority
BR
Brazil
Prior art keywords
treating
infection
disease
improving
preventing
Prior art date
Application number
BR112021024491A
Other languages
English (en)
Other versions
BR112021024491A2 (pt
Inventor
He Jian
M Kaufhold Robin
M Skinner Julie
Xie Jinfu
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112021024491A2 publication Critical patent/BR112021024491A2/pt
Publication of BR112021024491A8 publication Critical patent/BR112021024491A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA, E, USO DE UMA COMPOSIÇÃO DE VACINA IMUNOGÊNICA. A presente invenção fornece métodos para o tratamento de pacientes através da administração de uma vacina imunogênica multivalente de conjugado polissacarídeo-proteína pneumocócica que compreende um conjugado de polissacarídeo-proteína de sorotipo 35B de S. pneumoniae, não compreende um conjugado de polissacarídeo-proteína de sorotipo 29 de S. pneumoniae e fornece proteção contra sorotipo 29 de S. pneumoniae.
BR112021024491A 2019-06-05 2020-06-01 Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição BR112021024491A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857534P 2019-06-05 2019-06-05
PCT/US2020/035511 WO2020247301A1 (en) 2019-06-05 2020-06-01 Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29

Publications (2)

Publication Number Publication Date
BR112021024491A2 BR112021024491A2 (pt) 2022-02-15
BR112021024491A8 true BR112021024491A8 (pt) 2023-04-11

Family

ID=73653320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024491A BR112021024491A8 (pt) 2019-06-05 2020-06-01 Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição

Country Status (10)

Country Link
US (1) US20220218812A1 (pt)
EP (1) EP3980050A4 (pt)
JP (1) JP2022535064A (pt)
KR (1) KR20220016964A (pt)
CN (1) CN114025784A (pt)
AU (1) AU2020289048A1 (pt)
BR (1) BR112021024491A8 (pt)
CA (1) CA3142697A1 (pt)
MX (1) MX2021014948A (pt)
WO (1) WO2020247301A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
MX2020002557A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311976A1 (en) * 2009-10-19 2011-04-20 Azienda Ospedaliero-Universitaria Meyer Method for Streptococcus Pneumoniae diagnosis and serotyping
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
EP3436061A4 (en) * 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
JP2019529497A (ja) * 2016-09-30 2019-10-17 バイオロジカル イー リミテッド 多糖類−タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
MA47223A (fr) * 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels

Also Published As

Publication number Publication date
EP3980050A1 (en) 2022-04-13
CN114025784A (zh) 2022-02-08
MX2021014948A (es) 2022-01-24
WO2020247301A1 (en) 2020-12-10
US20220218812A1 (en) 2022-07-14
AU2020289048A1 (en) 2021-12-09
CA3142697A1 (en) 2020-12-10
JP2022535064A (ja) 2022-08-04
KR20220016964A (ko) 2022-02-10
EP3980050A4 (en) 2023-08-02
BR112021024491A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
BR112021024491A8 (pt) Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
ECSP20032085A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
DOP2021000127A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
BR112013006396A2 (pt) composições imunogênicas
BR112016015525A2 (pt) composições imunogênicas compreendendo antígenos sacarídeos capsulares conjugados e uso
BR112018000087A2 (pt) composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
MX2020006662A (es) Vacuna combinada intradermica contra mycoplasma y circovirus porcino.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112021026499A2 (pt) Formulação gastrorretentiva de liberação prolongada contra helicobacter pylori
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?
BR112018069219A2 (pt) uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
RU2021138121A (ru) Способы лечения пациентов иммуногенной композицией, защищающей от серотипа 29 s. pneumoniae
MX2019013779A (es) Vacuna que comprende toxoides de clostridium.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)